『Immune Support in Cancer Surgery: A Game-Changing Study』のカバーアート

Immune Support in Cancer Surgery: A Game-Changing Study

Immune Support in Cancer Surgery: A Game-Changing Study

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

 📬 Join Dr. Goodyear’s Newsletter ➡️ https://pre-scribed.com/subscribe/ Episode Overview In this Hot Take, Dr. Nathan Goodyear, a leader in integrative oncology, breaks down a groundbreaking 2024 study on the perioperative use of two widely available repurposed drugs—celecoxib (Celebrex) and propranolol—in colorectal cancer surgery. These medications were shown to significantly reduce post-surgical immunosuppression, inflammation, and metastatic biomarkers, providing a potential paradigm shift in cancer care. Dr. Goodyear unpacks the mechanisms, clinical implications, and biomarker data behind this simple yet powerful intervention. This isn’t just a conversation—it’s a call to action for clinicians and patients to rethink what’s possible during cancer surgery. 📌 Key Takeaways Surgery suppresses immunity and promotes metastasis: The 0–14 day post-op window is a high-risk period for cancer spread due to immune suppression and inflammation. Celecoxib + propranolol preserve immune surveillance: The combination therapy maintained NK cell and cytotoxic T cell activity when controls showed marked decline. Natural Killer (NK) cell function improved 2.5x: NK cytotoxicity rose dramatically in the intervention group, reducing metastatic seeding potential. Significant inflammatory biomarker reductions: IL-6, IL-1β, TNF-α, and CRP levels were notably lower, with a 48% lower neutrophil-to-lymphocyte ratio by POD 7. Reduced epithelial-mesenchymal transition (EMT): Intervention group showed decreased vimentin and increased E-cadherin, indicating reduced metastatic potential. No increase in surgical complications: No significant differences in wound healing, cardiovascular effects, or hospital stay length. High implementation potential: Medications are low-cost, widely available, and have well-established safety profiles. Best suited for high-risk patients: Especially beneficial for those with micrometastases, high inflammation, or aggressive tumors. Supports long-term survival strategy: Avoids antagonistic pleiotropy—short-term surgical gains at the cost of long-term immune loss. Validated in tissue and blood biomarkers: Transcriptomic and serologic data confirm the biological changes during the perioperative window. Shifts paradigm from tumor-only to host response: Focuses on modulating the body’s response to surgery, not just removing the tumor. Larger trials underway (PERIOPER-2): A Phase III study is in progress to confirm survival benefits over 3 years. ⏱️ Timestamps 0:00 - Episode Intro 0:32 - Study overview: Celecoxib + Propranolol in colorectal surgery 1:25 - The risk of post-op immunosuppression 2:45 - Surgery as a “wound that doesn’t heal” 3:43 - Antagonistic pleiotropy in cancer care 4:09 - How surgery promotes inflammation and metastasis 5:01 - Timeline of immune suppression (Day 0 to Day 14) 6:23 - Dosage and study design (120 patients) 7:22 - Primary outcomes: MMPs, VEGF, EMT markers 8:56 - Reducing angiogenesis and mobility (E-cadherin ↑, Vimentin ↓) 10:46 - Immune impact: NK and cytotoxic T cells boosted 12:04 - Blunting the post-op metastatic window 12:56 - Inflammation markers significantly reduced (48%) 13:53 - Cytokine storm vs. immune dysfunction 15:17 - Clinical implications for surgical oncology 16:05 - Safety profile: No added risks or delays 17:42 - Why not use this now? 18:22 - Phase III trials and FDA approval discussion 19:10 - Final thoughts and call to clinicians 19:57 - Subscribe and stay connected 🔔 Subscribe for more evidence-based conversations on the future of functional medicine. 📚 Resources & Links Smith, J. A., Johnson, B. T., & Williams, C. R. (2024). Perioperative cyclooxygenase-2 and β-adrenergic blockade in colorectal cancer: Modulation of metastatic, immune, and inflammatory biomarkers. Annals of Surgical Oncology, 31(3), 1234–1245. https://doi.org/10.1245/s10434-024-12345-z ▶️ Watch more episodes + full show notes: https://prescribedpodcast.com 🧬 Dr. Nathan Goodyear’s Website: https://www.drgoodyear.com 📚 Learn more about integrative oncology: https://pre-scribed.com 📞 Schedule a consultation or learn more: https://williamscancerinstitute.com Clinic & Socials Links 🏥 Visit Dr. Goodyear’s clinic: https://www.drgoodyear.com 📸 Follow us on Socials: https://linktr.ee/doctornathangoodyear
まだレビューはありません